Anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation in patients with high-risk CD30+lymphoma: a phase 1 study

Authors :: Grover, Natalie S
Hucks, George
Riches, Marcie L
Ivanova, Anastasia
Moore, Dominic T
Shea, Thomas C
Seegars, Mary Beth
Armistead, Paul M
Kasow, Kimberly A
Beaven, Anne W
Dittus, Christopher
Coghill, James M
Jamieson, Katarzyna J
Vincent, Benjamin G
Wood, William A
Cheng, Catherine
Morrison, Julia Kaitlin
West, John
Cavallo, Tammy
Dotti, Gianpietro
Serody, Jonathan S
Savoldo, Barbara
Source :: The Lancet Haematology; May 2024, Vol. 11 Issue: 5 pe358-e367, 10p
Publication Year :: 2024
Abstract: Chimeric antigen receptor (CAR) T cells targeting CD30 are safe and have promising activity when preceded by lymphodepleting chemotherapy. We aimed to determine the safety of anti-CD30 CAR T cells as consolidation after autologous haematopoietic stem-cell transplantation (HSCT) in patients with CD30+lymphoma at high risk of relapse.

Full Text Access

Tools